» Download Public Reports
About 1 300 reports
- Company report
- March 2013
- 10 pages
March 2013
... Commercial rollout of vitrogro in europe. Top international stories amgen reports positive phase-3 data for melanoma vaccine:- which it acquired as part of biovex that it bought two years ago for up to $1 ...
May 2013
... Of imugene platform linguet Is a proprietary drug delivery technology that improves the efficacy and safety of a diverse number of prescription and over the counter medicines. The platform technology ...
March 2013
... Commercial and licensing deals. In addition, we view diabetic nephropathy program and future partnerships in molecular diagnostics as an upside to our current target price, with strong ip around midkine ...
April 2013
... Formulated diclofenac by thermis. Top international stories positive data from vertex S cystic fibrosis drug:- boston-based vertex pharmaceuticals has reported positive data from a phase-2 clinical trial ...
March 2013
... In the 25-35 year old age group a recent analysis of the national cancer institute statistic showed that survival rates have not increased at all since 1975 cancer is the leading disease killer ...
March 2013
... For multiple suppliers Low marginal cost of production The (relevant) policy issue is what should the subsidised price be 6 Grattan analyses Identified the 50 drug-dose combinations that are highest ...
» Purchase Premium Reports
(From $ 125 - $ 3 500)
About 400 reports
- $ 3 500
- Industry report
- April 2013
- by GBI Research
Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants ...
February 2013
$ 2 000
This report provides data on the therapeutic development for Nausea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...
March 2013
$ 2 000
This report provides data on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...
March 2013
$ 2 000
This report provides data on the therapeutic development for Cough, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ...
April 2013
$ 2 000
This report provides data on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...
May 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: Given the country's increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is a highly attractive place for multinational ...
April 2013
$ 970
Healthy and wealthy: The market maintains mature growth as competition intensifies Pharmacies in Australia This market covers all pharmacies involved in the sale of prescription drugs and patent medicines. ...